Good morning and nice to see you again. A busy morning here on the Pharmalot corporate campus, where we have been hustling various short people off to the local school house for some learning. To cope, we are, of course, sipping that needed cup of stimulation. Please feel free to join us. Meanwhile, we are gearing up for another busy day of phone calls and our own version of R&D. And so here are some tidbits as you gear up for your own challenges. Hope all goes well and be in touch...
Allergan Licenses Drug For Retinal Disease (Reuters)
Osteoporosis Drug Linked To Rare Thigh Fractures (Wall Street Journal)
Ranbaxy May Pay $1B Fine For Manufacturing Problems (Economic Times)
Glaxo Is Ready To Settle Another 1,000 Avandia Lawsuits (Bloomberg News)
Merck And Astra Asthma Pills As Good As Inhalers: Study (Reuters)
Roche Study Disputes Findings On Avastin Vs. Lucentis (Financial Times)
Actelion Shareholders Reject First Elliott Proposals (Reuters)
Stem Cells Lays Off 20 Employees (San Francisco Business Journal)
EDITOR’S NOTE: Please check this space for updates throughout the morning